SABS Key Statistics, Chart & Performance
The current stock price of SABS is 3.71 USD. In the past month the price increased by 13.46%. In the past year, price decreased by -9.07%.
SABS Latest News, Press Relases and Analysis
SABS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.83 | 397.98B | ||
| AMGN | AMGEN INC | 14.42 | 169.83B | ||
| GILD | GILEAD SCIENCES INC | 14.82 | 150.54B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.61 | 112.81B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.13 | 76.32B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 793.06 | 53.43B | ||
| INSM | INSMED INC | N/A | 40.49B | ||
| NTRA | NATERA INC | N/A | 32.17B | ||
| BIIB | BIOGEN INC | 10.61 | 26.05B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.37 | 20.88B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.21B | ||
| INCY | INCYTE CORP | 14.82 | 18.68B |
Related stock screener links
About SABS
Company Profile
SAB Biotherapeutics, Inc. is a clinical-stage, biopharmaceutical company, which engages in advancing a new class of immunotherapies leveraging fully-human polyclonal antibodies. The company is headquartered in Miami Beach, Florida and currently employs 63 full-time employees. The company went IPO on 2021-01-12. The firm is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets or best-in-class against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. The Company’s lead product candidate, SAB-142, is a human anti-thymocyte globulin (ATG) focused on preventing or delaying the progression of T1D. SAB-142 is expected to reduce autoimmune beta cell destruction and delay progression or onset of T1D in patients with Stage III or Stage II T1D. The Company’s genetic engineering platform produces human, multi-targeted, high-potency immunoglobulins, without the need for human donors or convalescent plasma.
Company Info
SAB BIOTHERAPEUTICS INC
777 W 41St St, Suite 401
Miami Beach FLORIDA US
CEO: Samuel J. Reich
Employees: 63
Phone: 13058452813
SAB BIOTHERAPEUTICS INC / SABS FAQ
Can you describe the business of SAB BIOTHERAPEUTICS INC?
SAB Biotherapeutics, Inc. is a clinical-stage, biopharmaceutical company, which engages in advancing a new class of immunotherapies leveraging fully-human polyclonal antibodies. The company is headquartered in Miami Beach, Florida and currently employs 63 full-time employees. The company went IPO on 2021-01-12. The firm is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets or best-in-class against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. The Company’s lead product candidate, SAB-142, is a human anti-thymocyte globulin (ATG) focused on preventing or delaying the progression of T1D. SAB-142 is expected to reduce autoimmune beta cell destruction and delay progression or onset of T1D in patients with Stage III or Stage II T1D. The Company’s genetic engineering platform produces human, multi-targeted, high-potency immunoglobulins, without the need for human donors or convalescent plasma.
Can you provide the latest stock price for SAB BIOTHERAPEUTICS INC?
The current stock price of SABS is 3.71 USD. The price decreased by -1.33% in the last trading session.
Does SAB BIOTHERAPEUTICS INC pay dividends?
SABS does not pay a dividend.
What is the ChartMill technical and fundamental rating of SABS stock?
SABS has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Which stock exchange lists SABS stock?
SABS stock is listed on the Nasdaq exchange.
What do analysts say about SAB BIOTHERAPEUTICS INC (SABS) stock?
12 analysts have analysed SABS and the average price target is 9.01 USD. This implies a price increase of 142.86% is expected in the next year compared to the current price of 3.71.
What is the expected growth for SABS stock?
The Revenue of SAB BIOTHERAPEUTICS INC (SABS) is expected to decline by -100% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
SABS Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to SABS. When comparing the yearly performance of all stocks, SABS is one of the better performing stocks in the market, outperforming 89.43% of all stocks.
SABS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to SABS. SABS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
SABS Financial Highlights
Over the last trailing twelve months SABS reported a non-GAAP Earnings per Share(EPS) of -3.03. The EPS increased by 48.62% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -11.65% | ||
| ROE | -12.94% | ||
| Debt/Equity | 0.02 |
SABS Forecast & Estimates
12 analysts have analysed SABS and the average price target is 9.01 USD. This implies a price increase of 142.86% is expected in the next year compared to the current price of 3.71.
For the next year, analysts expect an EPS growth of 40.35% and a revenue growth -100% for SABS